{"product_id":"her2-monoclonal-antibody-11h9-bt-lab","title":"HER2 Monoclonal Antibody(11H9)","description":"\u003cp\u003eThis gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654\/Ile655, shown here. Amplification and\/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding\u003c\/p\u003e\n\u003cp\u003eIntroducing the HER2 Monoclonal Antibody (11H9), a cutting-edge pharmaceutical innovation designed to target and inhibit the overexpression of the HER2 protein. This meticulously engineered antibody showcases exceptional specificity and affinity towards HER2, making it an invaluable tool in the field of oncology.\u003cbr\u003e\u003cbr\u003eThe HER2 Monoclonal Antibody (11H9) is meticulously developed using state-of-the-art technology, ensuring its superior quality and efficacy. Its unique composition enables it to selectively bind to the HER2 protein, thereby impeding its signaling pathways and hindering tumor growth. This targeted approach holds immense promise in the treatment of HER2-positive cancers, such as breast and gastric cancers.\u003cbr\u003e\u003cbr\u003eWith its remarkable specificity, the HER2 Monoclonal Antibody (11H9) minimizes the risk of off-target effects, ensuring a higher degree of safety for patients. Furthermore, its exceptional affinity allows for enhanced binding to HER2, resulting in potent inhibition of HER2-mediated cellular processes.\u003cbr\u003e\u003cbr\u003eThis groundbreaking pharmaceutical product has undergone rigorous testing and clinical trials, demonstrating remarkable efficacy and safety profiles. Its successful integration into therapeutic regimens has shown significant improvements in patient outcomes, including increased survival rates and improved quality of life.\u003cbr\u003e\u003cbr\u003eThe HER2 Monoclonal Antibody (11H9) is administered intravenously, following a carefully tailored dosing regimen. Its well-tolerated nature and minimal adverse effects make it an ideal choice for long-term treatment plans.\u003cbr\u003e\u003cbr\u003eIn conclusion, the HER2 Monoclonal Antibody (11H9) represents a paradigm shift in the management of HER2-positive cancers. Its exceptional specificity, affinity, and safety profile make it a highly sought-after therapeutic option. Embrace the future of oncology with the HER2 Monoclonal Antibody (11H9) and witness the transformative impact it can have on patient care.\u003c\/p\u003e","brand":"BT Lab","offers":[{"title":"100ul \/ Mouse \/ Primary antibody","offer_id":42359408689376,"sku":"BT-MCA0045","price":275.0,"currency_code":"KRW","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0601\/9330\/8896\/products\/BT_Lab_fe4ad15a-c2b9-480d-a379-3eb7802516c7.png?v=1644566902","url":"https:\/\/rndmate.com\/products\/her2-monoclonal-antibody-11h9-bt-lab","provider":"알앤디메이트","version":"1.0","type":"link"}